| Theme | New Development in Vitamin D Therapy | |
|---|---|---|
| Title | Calcitriol | |
| Publish Date | 2001/02 | |
| Author | Eriko Kinugasa | Department of Internal Medicine, Showa University, Fujigaoka Hospital |
| Author | Hideki Kato | Department of Internal Medicine, Showa University, Fujigaoka Hospital |
| Author | Tsuyoshi Hasegawa | Department of Internal Medicine, Showa University, Fujigaoka Hospital |
| [ Summary ] | Intravenous calcitirol (Ro 21-5535; Ro), doses ranging from 0.5 to 2µg/HD, showed dose-dependent effects on parathyroid hormone (PTH) suppression and a rise of serum calcium in the treatment of secondary hyper parathyroidism with chronic hemodialysis patients. An initial dose of 1µg/HD is thought to he appropriate, from the results of several clinical studies. The most frequent side-effects are hypercalcemia and related symptoms, which were observed in about 24% of the patients in long-term studies, although discontinuation of Ro administration rapidly returned serum calcium to previous levels. Though it is difficult to minimize hypercalcemia with PTH suppression, timely decrement of Rodosage, when hypercalcemic tendency are observed is mandatory to prevent serious hyper calcemia and also to avoid low turnover bone disease. | |